CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
US stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.
Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.
Oil prices fell after Axios said the US, Iran and Oman were nearing an interim deal to reopen the Strait of Hormuz. Houthi threats to escalate attacks on Saudi tankers and Trump’s comments added volatility. Bloomberg Intelligence expects Q2 earnings up about 23% and 86% of 387 S&P 500 firms beat estimates. Markets also priced rate-hike odds for the FOMC and ECB.
Over the past 7 days, alphai's AI scored 15 news stories mentioning CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.). Coverage has skewed bullish: 14 bullish, 1 neutral, and 0 bearish.
Recent CRL coverage spans market movers, financial news and earnings.
In the last 30 days, CRL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.3M). The most active reporter was Parisotto Shannon M, CEVP, Disc & Safety Assessment, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
CRL’s revenue beat is a positive fundamental driver for the stock’s next trading window.
Raised adjusted EPS guidance tied to stronger DSA momentum and margin drivers, partially offset by GAAP pressure from divestiture losses.
A revenue beat with a double-digit rally points to improving sentiment toward CRO demand and earnings quality.
This is a routine insider sale disclosure tied to a pre-arranged 10b5-1 plan, with limited direct signal for near-term fundamentals.
Upgrade plus raised guidance and beat suggests near-term momentum could persist, but upside may be capped if biotech funding tailwinds fade.
alphai scores every news story that mentions CRL with an AI model for sentiment and relevance, and aggregates insider trades from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
US stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.
7 min readCharles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.
6 min readOil prices fell after Axios said the US, Iran and Oman were nearing an interim deal to reopen the Strait of Hormuz. Houthi threats to escalate attacks on Saudi tankers and Trump’s comments added volatility. Bloomberg Intelligence expects Q2 earnings up about 23% and 86% of 387 S&P 500 firms beat estimates. Markets also priced rate-hike odds for the FOMC and ECB.
7 min readParisotto Shannon M (CEVP, Disc & Safety Assessment) sold 5,046 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $263.00 ($1.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readJPMorgan upgraded Charles River Laboratories (CRL) to overweight from neutral and raised its 12-month price target to $310 from $180, citing stronger momentum in its discovery and safety assessment business. Charles River reported 2Q EPS of $3.02 (ex items) vs $2.74 expected and revenue of about $1.0B vs $977.2M consensus, and lifted 2026 guidance to $11.15-$11.45.
4 min read24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
4 min readNasdaq 100 E-mini futures fell 0.42% as Western Digital and SanDisk dropped after FQ1 guidance missed expectations. WDC slid over 14% and Sandisk fell over 9% in pre-market, weighing on AI-related stocks. The article also cites mixed U.S. data, Fed officials’ rate comments, and upcoming earnings and economic releases.
7 min readA dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readS&P 500 and Dow hit record highs on Middle East peace deal hopes, while Nasdaq lagged as SpaceX and AMD fell after earnings. SpaceX reported nearly doubled revenue and narrower losses but shares dropped 7.3% on spending concerns and potential post-IPO lock-up expiry. AMD shares fell 6.5% despite higher revenue guidance; Nvidia rose 3.7%.
7 min readEvercore ISI raised its price target for Charles River Laboratories International (NYSE:CRL) to $300 from $260 and kept an Outperform rating, citing a return to organic revenue growth in the first quarter and a DSA book-to-bill of 1.19x. The firm projects 21% adjusted operating income margins for FY2026 and values shares at 23x 2027 earnings.
2 min read
